TETRAVECTA

What this means for you

Not registered yet, but its 04 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

98432248

Mark type

Stylized text

Filed

04 Mar 2024

Attorney of record

Rebeccah Gan

Goods and services

• Class 040 — Treatment of materials: Custom manufacture of products relating to biotechnology, namely, custom manufacture of biopharmaceuticals for use in cell and gene therapies; custom manufacture of gene and cell-based therapy products, namely, genetically engineered cells and tissues for cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of biopharmaceuticals used in cell and gene therapies, and biopharmaceutical preparations; biotechnology contract manufacturing services, namely, contract manufacturing in the field of pharmaceuticals and biopharmaceuticals for cell and gene therapy using biological organisms in the manufacturing process; contract manufacturing services of gene and cell-based therapy products, namely, biopharmaceuticals for cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of biopharmaceuticals for cell and gene therapies and biopharmaceutical products, namely, biopharmaceuticals for cell and gene therapies; contract manufacturing services of technology for biopharmaceutical products and gene and cell-based products, namely, custom manufacture of biopharmaceuticals for cell and gene therapies; contract manufacturing services of technology for viral vectors, retroviral vectors, lentiviral vectors, adeno-associated viral vectors, adenoviral vectors, and non-vector preparations, namely, custom manufacture of pharmaceuticals and biopharmaceuticals for cell and gene therapies
• Class 042 — Scientific and technological services: Research and laboratory analytic and diagnostic services, namely, scientific research, biochemical research, research laboratory analysis services in the field of gene therapy and biochemistry; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; product, viral vector product and analytic assay product development for others; laboratory services, namely, scientific laboratory services and biological research laboratory services; research and development services, namely, gene therapy research; genetic engineering laboratories, namely, scientific research in the field of genetic engineering provided in genetic engineering laboratories and biochemistry laboratories providing research and development in the field of biochemistry; scientific and technological services and research, namely, scientific research, analysis, testing in the fields of gene therapy and biochemistry; industrial analysis services, namely, providing testing analysis services with respect to gene-therapy based product manufacturing for industrial purposes; provision of information relating to scientific research; provision of scientific information in the fields of gene therapy and biochemistry; product research and scientific analysis of cell and gene therapies relating to drug discovery and product development for others; scientific advisory services relating to biochemistry; scientific consultancy services relating to biochemistry; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals

Owner

• Oxford BioMedica Plc, Oxford, GB

Prosecution history

• 20 Oct 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
• 20 Oct 2025 — LETTER OF SUSPENSION E-MAILED
• 20 Oct 2025 — SUSPENSION LETTER WRITTEN
• 17 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 17 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 17 Oct 2025 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
• 09 Sept 2025 — NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
• 09 Sept 2025 — INQUIRY TO SUSPENSION E-MAILED
• 09 Sept 2025 — SUSPENSION INQUIRY WRITTEN
• 22 Jul 2025 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
• 21 Jan 2025 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
• 21 Jan 2025 — LETTER OF SUSPENSION E-MAILED
• 21 Jan 2025 — SUSPENSION LETTER WRITTEN
• 24 Dec 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 23 Dec 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE